Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators
Executive Summary
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”
You may also be interested in...
COVID-19 Trial Changes Are "Propulsive Force" For Digital Adoption
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
US FDA Outlines Wishlist For Decentralized Clinical Trials
As interest in conducting remote decentralized clinical trials grows, a senior US regulator explains what companies should consider when planning such trials.
The Evolving Door? What Having A ‘Big Data’ Commissioner Might Mean For US FDA
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.